Loading
companiesCompany
Jacobio Pharmaceuticals
Jacobio Pharmaceuticals is a Chinese developer in Beijing that sponsors 6 registered cancer trials of JAB-30355 and JAB-2485.
Also called: Jacobio Pharmaceuticals Co., Ltd.
Overview
Jacobio Pharmaceuticals appears on ClinicalTrials.gov as the industry sponsor of 6 interventional cancer trials (phase 1/2), testing JAB-30355, JAB-2485, JAB-23E73, JAB-8263 in solid tumors, er+ breast cancer, triple negative breast cancer, tnbc, arid1a gene mutation. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.
Headquarters
Beijing, China, CN
Scorecard
All companies#271of 1244 companies, score 17
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +6
1 approved, 0 in phase 3, 0 earlier, 1 targets, 8 registry studies. Formula on the scorecards page.
Type
Website
ApprovedOral covalent KRAS G12C inhibitor
Glecirasib is Jacobio's KRAS G12C inhibitor, approved in China in 2024 for previously treated non-small cell lung cancer with that mutation, and in a phase 3 trial against docetaxel.
Similar pages
- CompanyBeijing Gene Key Life Technology
Shares the tags china, registry-only.
- CompanyBeijing Konruns Pharmaceutical
Shares the tags china, registry-only.
- CompanyBeijing Mabworks Biotech
Shares the tags china, registry-only.
- CompanyBeijing Pearl Biotechnology Limited Liability Company
Shares the tags china, registry-only.
- CompanyBeijing Scitech-Mq Pharmaceuticals
Shares the tags china, registry-only.
- CompanyBeijing Tide Pharmaceutical
Shares the tags china, registry-only.
- CompanyBinhui Biopharmaceutical
Shares the tags china, registry-only.
- CompanyChengdu Zenitar Biomedical Technology
Shares the tags china, registry-only.
cancers
drugs
ApprovedOral covalent KRAS G12C inhibitor
trials
A First-in-Human, JAB-8263 in Adult Patients With Advanced TumorsA Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene AlterationJAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS AlterationJAB-2485 Activity in Adult Patients With Advanced Solid TumorsJAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C MutationStudy of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations